PARTNERSHIP FOR DIABETES
Aspect Biosystems & Novo Nordisk
Since 2023, Aspect Biosystems and Novo Nordisk have collaborated to develop cellular medicines designed to replace, repair or supplement biological functions to deliver truly disease-modifying therapies. This collaboration reflects our shared mission to accelerate the development of potentially curative medicines for serious diseases.
In January 2026, Aspect Biosystems and Novo Nordisk entered a new phase of their partnership. This partnership evolution includes the strategic integration of Novo Nordisk technologies into Aspect Biosystems, including stem cell-derived islet cell and hypoimmune cell engineering technologies.
